sclcM1201764A_S68.txt
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.590
- ANGIOGENESIS+0.580
- ALLOGRAFT_REJECTION+0.530
- IL6_JAK_STAT3_SIGNALING+0.530
- PANCREAS_BETA_CELLS+0.510
- INFLAMMATORY_RESPONSE+0.500
- COMPLEMENT+0.490
- HYPOXIA+0.480
- TNFA_SIGNALING_VIA_NFKB+0.480
- INTERFERON_GAMMA_RESPONSE+0.470
Top 10 suppressed
- MYC_TARGETS_V2-0.380
- DNA_REPAIR-0.370
- G2M_CHECKPOINT-0.360
- E2F_TARGETS-0.350
- MITOTIC_SPINDLE-0.340
- MYC_TARGETS_V1-0.320
- WNT_BETA_CATENIN_SIGNALING-0.190
- TGF_BETA_SIGNALING-0.130
- HEME_METABOLISM+0.030
- PI3K_AKT_MTOR_SIGNALING+0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
0 twins match this tumor's tissue · 10 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0410 | Med | Medulloblastoma | 0.933 |
| 2 | BS_1TPWFSK6 | subependymal giant cell astrocytoma(SEGA) | — | 0.930 |
| 3 | BS_YEQVW4ND | low-grade glioma | — | 0.910 |
| 4 | BS_55JW3HFM | Ganglioglioma | — | 0.909 |
| 5 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.908 |
| 6 | MDT-AP-0385 | Med | Medulloblastoma | 0.908 |
| 7 | SRR820256 | GTEX | — | 0.904 |
| 8 | MDT-AP-2774 | Med | Medulloblastoma | 0.904 |
| 9 | SRR663693 | GTEX | — | 0.902 |
| 10 | BS_8VAZSJEN | pilocytic astrocytoma | — | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.590 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.580 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.510 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.490 | Inavolisib | — uncovered |
| HYPOXIA | 0.480 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.440 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.420 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |